Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00696
|
|||||
| Drug Name |
Phenoxybenzamine
|
|||||
| Synonyms |
2-(N-Benzyl-2-chloroethylamino)-1-phenoxypropane; 688A; A 688; Bensylyt; Bensylyt NEN; Bensylyte; Benzyl(2-chloroethyl)-(1-methyl-2-phenoxyethyl)amine; Benzylyt; Dibenylene; Dibenylin; Dibenyline; Dibenziran; Dibenzylene; Dibenzylin; Dibenzyline (TN); Dibenzyran; Fenossibenzamina; Fenossibenzamina [DCIT]; Fenoxibenzamina; Fenoxibenzamina [INN-Spanish]; N-(2-Chloroethyl)-N-(1-methyl-2-phenoxyethyl)benzenemethanamine; N-(2-Chloroethyl)-N-(1-methyl-2-phenoxyethyl)benzylamine; N-(2-chloroethyl)-N-(phenylmethyl)-1-(phenyloxy)propan-2-amine; N-Phenoxyisopropyl-N-benzyl-beta-chloroethylamine; N-benzyl-N-(2-chloroethyl)-1-phenoxypropan-2-amine; POB HCl; Phenoxybenzamine (INN);Phenoxybenzamine [INN:BAN]; Phenoxybenzamine Hcl; Phenoxybenzaminum; Phenoxybenzaminum [INN-Latin]
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Malignant phaeochromocytoma [ICD11:2D11.1] | Approved | [1] | |||
| Benign prostatic hypertrophy [ICD11:GA90] | Approved | [1] | ||||
| Malignant essential hypertension [ICD11:BA00] | Approved | [1] | ||||
| Therapeutic Class |
Antihypertensive Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C18H22ClNO
|
|||||
| Canonical SMILES |
CC(COC1=CC=CC=C1)N(CCCl)CC2=CC=CC=C2
|
|||||
| InChI |
InChI=1S/C18H22ClNO/c1-16(15-21-18-10-6-3-7-11-18)20(13-12-19)14-17-8-4-2-5-9-17/h2-11,16H,12-15H2,1H3
|
|||||
| InChIKey |
QZVCTJOXCFMACW-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 59-96-1
|
|||||
| Pharmaceutical Properties | Molecular Weight | 303.8 | Topological Polar Surface Area | 12.5 | ||
| Heavy Atom Count | 21 | Rotatable Bond Count | 8 | |||
| Hydrogen Bond Donor Count | 0 | Hydrogen Bond Acceptor Count | 2 | |||
| XLogP |
4.4
|
|||||
| PubChem CID | ||||||
| PubChem SID |
10529050
,11121824
,11122304
,11335975
,11361214
,11363032
,11363272
,11365594
,11365834
,11368156
,11368396
,11371195
,11371196
,11373757
,11374297
,11376318
,11376558
,11462186
,11466972
,11468092
,11485565
,11486803
,11489631
,11492584
,11494192
,14873959
,26752309
,26752310
,29223852
,4448492
,46507191
,47291177
,47365231
,47515348
,47662322
,47810788
,47885450
,48185031
,48185032
,48259269
,48334533
,48416417
,49698954
,49893224
,50105233
,50105234
,50319296
,7980292
,8152929
,9639
|
|||||
| ChEBI ID |
CHEBI:8077
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | 1-Oct | Transporter Info | Organic cation transporter 1 | Substrate | [2] | |
| References | ||||||
| 1 | Phenoxybenzamine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.